Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NVO
stocks logo

NVO

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
77.83B
+14.35%
--
--
83.26B
+16.76%
--
--
92.96B
+8.49%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Novo Nordisk A/S (NVO) for FY2025, with the revenue forecasts being adjusted by -4.12% over the past three months. During the same period, the stock price has changed by -24.75%.
Revenue Estimates for FY2025
Revise Downward
down Image
-4.12%
In Past 3 Month
Stock Price
Go Down
down Image
-24.75%
In Past 3 Month
9 Analyst Rating
up Image0
Wall Street analysts forecast NVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 92.08 USD with a low forecast of 61.00 USD and a high forecast of 136.47  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
5 Hold
1 Sell
Hold
up Image0
Current: 68.170
sliders
Low
61.00
Averages
92.08
High
136.47
up Image0
Current: 68.170
sliders
Low
61.00
Averages
92.08
High
136.47
BMO Capital
Evan David Seigerman
Buy
to
Hold
Downgrades
$105 → $64
2025-04-17
Reason
BMO Capital
Evan David Seigerman
Price Target
$105 → $64
2025-04-17
Downgrades
Buy
to
Hold
Reason
BMO Capital downgraded Novo Nordisk (NVO) to Market Perform from Outperform with a price target of $64, down from $105. The company's obesity competitor Eli Lilly (LLY) has made sizable advancements in its commercial and clinical portfolio, causing it to overtake Novo's early lead, the analyst tells investors in a research note. The firm says updates from Lilly's oral GLP1, orforglipron, are likely to pressure Novo shares, which will only be compounded by what it expects to be "softer" Q1 results. BMO is moving to the sidelines until Novo can demonstrate clinical and commercial "prowess."
UBS
Jo Walton
Strong Sell
to
Strong Buy
Upgrades
n/a
2025-01-08
Reason
UBS
Jo Walton
Price Target
n/a
2025-01-08
Upgrades
Strong Sell
to
Strong Buy
Reason
UBS analyst upgraded Novo Nordisk to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is "well placed" to continue to benefit from the high demand for GLP-1 medications in the near-term, and while the CagriSema Phase 3 data in obesity was disappointing, it is still a higher efficacy treatment that could still show differentiation in type 2 diabetes. UBS is a buyer of weakness and says shares are at an attractive entry point following the "overdone" selloff.
BMO Capital
Evan David Seigerman
Buy
Maintains
$156 → $105
2024-12-23
Reason
BMO Capital
Evan David Seigerman
Price Target
$156 → $105
2024-12-23
Maintains
Buy
Reason
BMO Capital lowered the firm's price target on Novo Nordisk (NVO) to $105 from $156 and keeps an Outperform rating on the shares after CagriSema's Phase 3 data readout failed to meet investor expectations. CagriSema was supposed to best Eli Lilly's (LLY) Zepbound, but missed the mark on efficacy and tolerability, which "cuts the margin of error for execution in 2025," so Q4 results "cannot miss and the 2025 guide must be strong," the analyst tells investors. Given the data, the firm is cutting its Novo price target, but thinks the reaction in shares today has been "overdone," the analyst added.
Cantor Fitzgerald
Louise Chen
Buy
Reiterates
$160
2024-11-06
Reason
Cantor Fitzgerald
Louise Chen
Price Target
$160
2024-11-06
Reiterates
Buy
Reason
BMO Capital
Evan David Seigerman
Buy
Maintains
$160 → $156
2024-10-17
Reason
BMO Capital
Evan David Seigerman
Price Target
$160 → $156
2024-10-17
Maintains
Buy
Reason
BMO Capital analyst Evan Seigerman lowered the firm's price target on Novo Nordisk to $156 from $160 and keeps an Outperform rating on the shares as part of a broader research note previewing Q3 results in BioPharma. Looking at script growth for Ozempic and Wegovy from Q2, the firm sees 4% and 24% growth, respectively, but while growth continues to be impressive, sell-side estimates may now be catching up to this growth, the analyst tells investors in a research note. Novo's Victoza scripts have declined nearly 50% from Q2 however as patients and providers transition to more efficacious agents Mounjaro / Ozempic, the firm added.
Cantor Fitzgerald
Louise Chen
Buy
Reiterates
$160
2024-10-10
Reason
Cantor Fitzgerald
Louise Chen
Price Target
$160
2024-10-10
Reiterates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Novo Nordisk A/S (NVO.N) is 15.95, compared to its 5-year average forward P/E of 28.63. For a more detailed relative valuation and DCF analysis to assess Novo Nordisk A/S 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Undervalued
5Y Average PE
28.63
Current PE
15.95
Overvalued PE
34.04
Undervalued PE
23.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Undervalued
5Y Average EV/EBITDA
20.42
Current EV/EBITDA
11.91
Overvalued EV/EBITDA
24.20
Undervalued EV/EBITDA
16.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Undervalued
5Y Average PS
9.78
Current PS
5.47
Overvalued PS
11.74
Undervalued PS
7.82

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 764.45% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

NVO News & Events

Events Timeline

(ET)
2025-05-22
09:42:56
Evernorth weight loss drug price point attractive compared to Hims, says Truist
select
2025-05-22
09:39:42
Cigna's Evernorth caps monthly weight loss drug cost at $200
select
link
2025-05-22
08:15:00
Novo Nordisk launches initiative for access to its legal semaglutide
select
Sign Up For More Events
Sign Up For More Events

News

Preview
5.0
00:12 AMCNBC
We’re adding to our position in this out-of-favor, high-quality drugmaker stock

  • Eli Lilly Stock Purchase: Jim Cramer's Charitable Trust is buying 10 shares of Eli Lilly, increasing its holdings to 125 shares and raising its portfolio weighting in the stock to 2.65%. The stock has recently dropped about 20% due to concerns over tariffs, drug pricing policies, and competition from Novo Nordisk.

  • Market Position and Future Outlook: Despite current challenges, Eli Lilly's stock is trading at a 52-week low, with potential for recovery as it prepares to launch both injectable and oral GLP-1 medications next year, which are expected to enhance its market share in the growing obesity treatment sector.

Preview
5.0
05-22TipRanks
Novo Nordisk Recruits Ex-CEO to Help Pick New Boss

  • Leadership Transition at Novo Nordisk: Former CEO Lars Rebien Sørensen returns as a board observer to guide the company through a critical leadership transition, following the departure of current CEO Lars Fruergaard Jørgensen amid competitive pressures in the U.S. market.

  • Market Sentiment and Analyst Ratings: Analysts have a neutral stance on Novo Nordisk's stock, with a consensus rating of Hold, indicating potential for recovery despite mixed sentiments; the average 12-month price target suggests a significant upside from its current trading price.

Preview
5.0
05-22SeekingAlpha
Novo Nordisk promotes Wegovy for new customers as compounding ban takes effect

  • Novo Nordisk's New Initiative: The company is promoting its weight loss therapy Wegovy for self-paying patients, offering the first month at $199 and subsequent months at $499, coinciding with a deadline for ceasing illegal semaglutide copies.

  • Partnerships and Offers: Telehealth firm LifeMD has introduced a bundled offer for Wegovy and its virtual weight management program at $299 for new patients, as part of partnerships with Novo Nordisk to enhance accessibility.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Novo Nordisk A/S (NVO) stock price today?

The current price of NVO is 68.17 USD — it has decreased -0.04 % in the last trading day.

arrow icon

What is Novo Nordisk A/S (NVO)'s business?

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

arrow icon

What is the price predicton of NVO Stock?

Wall Street analysts forecast NVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 92.08 USD with a low forecast of 61.00 USD and a high forecast of 136.47 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Novo Nordisk A/S (NVO)'s revenue for the last quarter?

Novo Nordisk A/S revenue for the last quarter amounts to 11.01B USD, increased 15.63 % YoY.

arrow icon

What is Novo Nordisk A/S (NVO)'s earnings per share (EPS) for the last quarter?

Novo Nordisk A/S. EPS for the last quarter amounts to 0.92 USD, increased 10.84 % YoY.

arrow icon

What changes have occurred in the market's expectations for Novo Nordisk A/S (NVO)'s fundamentals?

The market is revising Downward the revenue expectations for Novo Nordisk A/S (NVO) for FY2025, with the revenue forecasts being adjusted by -4.12% over the past three months. During the same period, the stock price has changed by -24.75%.
arrow icon

How many employees does Novo Nordisk A/S (NVO). have?

Novo Nordisk A/S (NVO) has 63370 emplpoyees as of May 23 2025.

arrow icon

What is Novo Nordisk A/S (NVO) market cap?

Today NVO has the market capitalization of 229.30B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free